Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | PKLR | P30613 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | FABP1 | P07148 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765251 | 0.86 | F2 (0.59) | MEN1KMT2ATP53PKLRALDH1A1 | |
| SCHEMBL6762133 | 0.80 | POLB (0.53) | MEN1KMT2AALDH1A1PKM | |
| SCHEMBL7352541 | 0.77 | PKLR (0.48) | MEN1KMT2ATP53PKLRALDH1A1 | |
| SCHEMBL6633986 | 0.76 | PKLR (0.54) | MEN1KMT2APKLRALDH1A1GAA | |
| SCHEMBL2690153 | 0.75 | MEN1 (0.66) | MEN1KMT2ATP53PKLRALDH1A1 | |
| SCHEMBL8524454 | 0.75 | PKLR (0.49) | MEN1KMT2APKLRALDH1A1GAA | |
| SCHEMBL6570560 | 0.75 | F2 (0.45) | HTT | |
| SCHEMBL8525044 | 0.75 | PKLR (0.49) | MEN1KMT2ATP53PKLRALDH1A1 | |
| SCHEMBL7358689 | 0.75 | NTSR1 (0.67) | MEN1KMT2ATP53PKLRALDH1A1 | |
| SCHEMBL8016188 | 0.74 | ALDH1A1 (0.49) | MEN1KMT2ATP53PKLRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-1414790-A1 | SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003000653-A1 | SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | NAT1, CYP3A5, CYP3A7 | MEN1 1875/4885KMT2A 1232/4885TP53 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.